Cancer cachexia: Pathophysiologic aspects and treatment options

Asian Pacific Journal of Cancer Prevention

Volumn 8, Issue 3, 2007, Pages 445-451

  Topkan, Erkan ^a   Yavuz, Ali Aydin ^b   Ozyilkan, Ozgur ^b  

^a Department of Radiation Oncology ^*  (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Anorexia; Cachexia; Cancer; Pathophysiology; Treatment

Indexed keywords

APPETITE STIMULANT;

CACHEXIA; DIET SUPPLEMENTATION; HUMAN; NEOPLASM; PATHOPHYSIOLOGY; REVIEW;

APPETITE STIMULANTS; CACHEXIA; DIETARY SUPPLEMENTS; HUMANS; NEOPLASMS;

EID: 44449130607     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Foster AC, Chen C, Markison S, et al (2005). MC4 receptor antagonists: a potential treatment for cachexia. Drugs, 8, 314-9.
2. Gordon JN, Goggin PM (2003). Thalidomide and its derivatives: emerging from wilderness. Postgrad Med J, 79, 127-32.
3. Gordon JN, Green SR, Goggin PM (2005). Cancer cachexia. Q J Med, 98, 779-88.
4. Goldberg RM, Loprinzi CL, Mailliard JA, et al (1995): Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized double blind placebo trial. J Clin Oncol, 13, 2856-9.
5. Grant M, Rivera L (1994). Impact of dietary counseling on quality of life in head and neck patients undergoing radiation therapy. Qual Life Res, 3, 77-8.
6. Hirai K, Hussey HJ, Barber MD, et al (1998). Biological evaluation of a lipid mobilizing factor isolated from the urine of cancer patients. Cancer Res, 58, 2359-65.
7. Inui A (2002). Cancer anorexia-cachexia syndrome. Current issues in research and management. CA Cancer J Clin, 52, 72-91.
8. Jahovic N, Sener G, Cevik H, et al (2004). Amelioration of methotrexate-induced enteritis by melatonin in rats. Cell Bichem Funct, 22, 169-78.
9. Kardinal CG, Loprinzi CL, Schaid DJ, et al (1990): A controlled trial of cyproheptadine in cancer pts with anorexia and/or cachexia. Cancer, 65, 2657-62.
10. Langhans W (2002). Peripheral mechanisms involved with catabolism. Curr Opin Clin Nutr Metab Care, 5, 419-26.
11. Lissoni P, Chilelli M, Villa S, et al (2003). Five year survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin. A randomized trial. J Pineal Res, 35, 12-5.
12. Lissoni P, Paolorossi P, Tancihi G, et al (1996). Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer, 32, 1340-3.
13. Loprinzi CL, Ellison NM, Schaid DJ, et al (1990). Controlled trial of megesterol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst, 82, 1127-32.
14. Loprinzi CL, Goldberg RM, Su JQ, et al (1994). Placebo controlled trial of hydralazine sulfate in patients with newly diagnosed NSCLC. J Clin Oncol, 12,1126-9.
15. Loprinzi CL, Kugler JW, Sloan J, et al (1999). Randomized comparison of megesterol acetate versus dexamethasone versus fluxymesterone for the treatment of cancer anorexia/ cachexia. J Clin Oncol, 17, 3299-3306.
16. Loprinzi CL, Kuross SA, O'Fallon JR, et al (1994). Randomized placebo controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol, 12, 1121-5.
17. Loprinzi CL, Michalak JC, Schaid DJ, et al (1993). Phase III evaluation of four doses of megesterol acetate as therapy for patients with cancer anorexia and/or anorexia. J Clin Oncol, 11, 762-7.
18. Lundholm K, Daneryd P, Bosaeus I, et al (2004). Palliative nutritional intervention in addition to cyclooxygenase and EPO treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer, 100, 1967- 77.
19. Lundholm K, Gelin J, Hyltander A, et al (1994). Antiinflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res, 54, 5602-6.
20. Markison S, Foster AC, Chen C, et al (2005). The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology, 146, 2766-73.
21. Mc Millan DC, Wigmore SJ, Fearon KC, et al (1999). A prospective randomized study of megesterol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer, 3, 495-500.
22. Mitch WE, Goldberg AL (1996). Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med, 335, 1897-905.
23. Moertel CG, Schutt AJ, Reitemeier RJ, et al (1974). Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer, 33, 1607-9.
24. Moses AWG, Slater C, Preston T, et al (2004). Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched withn-3 fatty acids. Br J Cancer, 90, 996-1002.
25. Pawlowski GJ: Cyproheptadine (1975). Weight gain and appetite stimulation in essential anorexic adults. Curr Ther Res Clin Exp, 18, 673-8.
26. Pende A, Musso NR, Vergassola C, et al (1990). Neuroendocrine effects of interferon alpha 2-a in healthy human subjects. J Biol Regul Homeost Agents, 4, 67-72.
27. Persson C, Glimeluis B (2002). The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Res, 22, 3661-8.
28. Ravasco P, Monteriro-Grillo I, Vidal PM, et al (2005). Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck, 27, 659-68.
29. Ravasco P, Monteiro-Grillo I, Vidal PM, et al (2005). Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol, 23, 1431-8.
30. Rossi Fanelli F, Cangiano C, Muscaritoli M, et al (1995). Tumour-induced changes in host metabolism: a possible marker of neoplastic disease. Nutrition, 11, 595-600.
31. Sampaio EP, Samo EN, Galilly R, et al (1991). Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med, 173, 699-703.
32. Smith HJ, Mukerji P, Tishdale MJ (2005). Attenuation of proteasome-induced proteolysis in skeletal muscle by (beta)- hydroxy-(beta)-methylbutyrate in cancer-induced muscle loss. Cancer Res, 65, 277-83.
33. Theobald DE, Kirsh KL, Holtsclaw E, et al (2002). An openlabel, cross-over trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage, 23, 442-7.
34. Tiao G, Hobler S, Wang JJ, et al (1997). Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest, 99, 163-8.
35. Tishdale MJ (2003). With a promising new treatment pathogenesis of cancer cachexia. J Support Oncol, 1,159-68.
36. Tishdale MJ (2004). Cancer Cachexia. Langenbecks Arch Surg, 389, 299-305.
37. Todorov P, Cariuk P, McDevitt T, et al (1996). Characterization of a cancer cachectic factor. Nature, 379, 739-42.
38. Topkan E, Karaoglu A (2006). Octreotide in management of chemoraradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. Oncology, 71, 354-60.
39. Topkan E, Selek U (2004). Eszamanli kemoradyoterapiye bagli diyarede ikinci basamak tedavide oktreotid'in yeri: 20 hastada on sonuclar (Article in Turkish). Int J Hematol Oncol, 14, 61-7.
40. Wagner KR, Mc Pherron AC, Winik N, et al (2002). Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol, 52, 832-6.
41. Wheeler MT, Snyder EC, Patterson MN, et al (1999). An E-box within the MHC IIB gene is bound by MyoD and is required for gene expression in fast muscle. Am J Physiol, 276, 1069- 78.
42. Wigmore SJ, Falconer SJ, Plester CE, et al (1995). Ibuprofen reduces energy expenditure an acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer, 72,185-8.
43. Williams AB, Decourten-Myers GM, Fischer JE, et al (1999). Sepsis stimulates release of myofilaments in skeletal muscleby a calcium-dependent mechanism. FASEB J, 13, 1435-43.
44. Wren AM, Seal LJ, Cohen MA, et al (2001). Ghrelin enhances appetite and increases food intake in humans. J Clin Oncol Endocrinol Metab, 86, 5992-5.
45. Wren AM, Small CJ, Ward HL, et al (2000). The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology, 14, 4325-8.
46. Yavuz MN, Yavuz AA, Aydin F, et al (2002). The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study. Int J Radiat Oncol Biol Phys, 54, 195-202.
47. Zidan J, Haim N, Beny A, et al (2001). Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol, 12, 227-9.